Research Status and Suggestion of Drug Clinical Trial Risk Management in China: Based on Co-word Analysis and Social Network Analysis Perspective
10.12026/j.issn.1001-8565.2023.03.06
- VernacularTitle:我国药物临床试验风险管理研究现状与建议——基于共词分析和社会网络分析视角
- Author:
Aiyi ZHANG
1
;
Siyuan XI
2
;
Zhongguang YU
3
,
4
Author Information
1. Faculty of Biomedical and Pharmaceutical Sciences, Beijing City University, Beijing 100094, China
2. Department of Pharmacy, China-Japan Friendship Hospital, Beijing 100029, China
3. Center for Respiratory, China-Japan Friendship Hospital, Beijing 100029, China
4. School of Economics and Management, Wuhan University, Wuhan 430072, China
- Publication Type:Journal Article
- Keywords:
Drug Clinical Trials;
Risk Management;
Co-word Analysis;
Social Network Analysis
- From:
Chinese Medical Ethics
2023;36(3):271-276
- CountryChina
- Language:Chinese
-
Abstract:
【Objective:】 To deeply understand the current situation and hotspots of drug clinical trials risk management in China. 【Methods:】 Co-word analysis and social network analysis were used to sort out the study results of risk management in drug clinical trials in China. 【Results:】 The trend of risk research of drug clinical trials in China was generally on the rise. The research hotspots focused on four areas: drug supervision and pharmacovigilance, risk management of drug clinical trial institutions, ethical review of drug clinical trials, and risk management of drug clinical trials. 【Conclusion:】 In the future, China should gradually improve the risk management system and supervision system of drug clinical trials, explore to establish a risk-based quality management and ethical review system of drug clinical trials, and enhance the risk assessment and coping ability of institutions.
